VIATRIS INC (VTRS)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for VTRS
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| VTRS | Chief Executive Officer and Director; Chief Executive Officer (principal executive officer) | 63 | ["Public Company Management", "Corporate Governance", "Global Business", "Healthcare Industry", "Risk Oversight/Compliance", "Strategy and M&A Experience", "Experience acquired during his more than 35 years in the healthcare industry"] | ["Science and Technology"] | 2026 |
Companies shown below are based on exact name match for the selected Director
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| GL | President | 52 | ["President of American Income since December 2011","Chief Marketing Officer of American Income since May 2004","Executive Vice President of American Income from May 2004 to December 2011"] | [] | 2014 |
Biography sourced from the proxy statement filing.
Chief Executive Officer (since April 2023), Viatris President (2018 - 2023), BioAtla, Inc. (NASDAQ: BCAB) ( BioAtla ), a global biotechnology company focused on the development of Conditionally Active Biologics antibody therapeutics Served as an executive (2008 - 2018), rising up the ranks from SVP and Global Head of Immunology to President of Inflammation and Immunology and then, beginning in 2017, President and COO, Celgene Corporation, a global biopharmaceutical company Key Skills and Experience: Public Company Management, Corporate Governance, Global Business, Healthcare Industry, Risk Oversight/Compliance, and Strategy and M&A Experience acquired during his more than 35 years in the healthcare industry, which has resulted in him possessing vast global commercial and pharmaceutical expertise and a proven ability to build, grow, and manage large complex organizations utilizing his substantial experience in developing and executing regulatory, clinical, and business development strategies as displayed by his time at BioAtla, where he built a clinical development structure that moved multiple assets from investigational new drug applications into late stage clinical development, drove the company s long-term strategic operational plan, and led all business development activities, and, prior to that, his time at Celgene where he led the company s oncology, inflammation, and immunology franchise, commercial operations, and clinical development Mr. Smith also brings Finance, Accounting, and Capital Markets and Human Capital Management Experience to the Board Other Current Public Company Boards: BioAtla (since 2020), Director Former Public Company Boards: Apexigen, Inc. (2019 - 2023 when it was acquired by Pyxis Oncology, Inc.), Director and most recently member of the Compensation and Corporate Governance and Nominating Committees Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) (2017 - 2020), Director and Chair of the Compensation and Nominating and Governance Committees Former Private Company Boards: Triumvira Immunologics, Inc. (2018 - 2023), Director and Chairman Refuge Biotechnologies, Inc. (2018 - 2022), Director F-star Therapeutics, Inc. (2018 - 2020), Chairman and member of the Audit and Nominating and Corporate Governance Committees